0001725160-22-000034.txt : 20220214
0001725160-22-000034.hdr.sgml : 20220214
20220214211022
ACCESSION NUMBER: 0001725160-22-000034
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220210
FILED AS OF DATE: 20220214
DATE AS OF CHANGE: 20220214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pinto Alexis
CENTRAL INDEX KEY: 0001819302
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39263
FILM NUMBER: 22636695
MAIL ADDRESS:
STREET 1: C/O ZENTALIS PHARMACEUTICALS, LLC
STREET 2: 530 SEVENTH AVENUE, SUITE 2201
CITY: NEW YORK
STATE: NY
ZIP: 10018
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Zentalis Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001725160
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 823607803
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1359 BROADWAY, SUITE 1710
CITY: NEW YORK
STATE: NY
ZIP: 10018
BUSINESS PHONE: (212) 433-3791
MAIL ADDRESS:
STREET 1: 1359 BROADWAY, SUITE 1710
CITY: NEW YORK
STATE: NY
ZIP: 10018
FORMER COMPANY:
FORMER CONFORMED NAME: Zentalis Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20200107
FORMER COMPANY:
FORMER CONFORMED NAME: Zeno Pharma, LLC
DATE OF NAME CHANGE: 20171212
4
1
wf-form4_164489099132680.xml
FORM 4
X0306
4
2022-02-10
0
0001725160
Zentalis Pharmaceuticals, Inc.
ZNTL
0001819302
Pinto Alexis
C/O ZENTALIS PHARMACEUTICALS, INC.
1359 BROADWAY, SUITE 1710
NEW YORK
NY
10018
0
1
0
0
Chief Legal Officer
Common Stock
2022-02-10
4
A
0
16405
0
A
22931
D
Common Stock
2022-02-14
4
S
0
614
50.1642
D
22317
D
Common Stock
2022-02-14
4
S
0
77
50.7472
D
22240
D
Stock Option (Right to Buy)
52.61
2022-02-10
4
A
0
38489
0
A
2032-02-09
Common Stock
38489.0
38489
D
Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date.
The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.58 to $50.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.58 to $50.81. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date.
/s/ Melissa B. Epperly, Attorney-in-Fact for Alexis Pinto
2022-02-14